Noteworthy Thursday Option Activity: AMD, GME, LLY

GameStop options printed 198,150 contracts (≈19.8M underlying shares), equal to roughly 181.3% of GME's one‑month ADV of 10.9M shares; the Feb 6, 2026 $25 call was most active with 14,548 contracts (~1.45M shares). Eli Lilly saw 53,944 option contracts (≈5.4M underlying shares), about 165.5% of its one‑month ADV of 3.3M, led by the Feb 27, 2026 $1,220 call with 1,368 contracts (~136,800 shares). The outsized relative volumes point to elevated positioning and potential near‑term volatility in both tickers.

Analysis

Market structure: The option flow (GME: 198,150 contracts ≈19.8M shares, 181% of ADV; LLY: 53,944 contracts ≈5.4M shares, 165% of ADV) implies outsized one‑sided demand for calls that mechanically forces market‑maker hedging (delta buys) into the underlyings. Winners are call buyers, liquidity providers who can charge wide spreads, and prime brokers financing margin; losers are short-dated option sellers and any passive holders facing transient price impact. Cross‑asset: sudden hedging buys can compress equity liquidity, widen bid/ask in single names and produce transient correlation spikes into equities and implied volatility; limited impact to rates/FX unless flows become systemic.

Risk assessment: Tail risk includes a retail‑led gamma squeeze (sharp intraday >30% moves), regulatory intervention (broker trading limits) or a single large block trade being misinterpreted — any could cause rapid unwind. Immediate (days): expirations (Feb 6 and Feb 27, 2026) and gamma will dominate; short term (weeks/months): realized volatility should mean‑revert and IV could compress 20–40% if flows cool; long term (quarters): fundamentals (LLY pipeline, GME business) reassert value. Hidden dependency: block OTM calls may be part of OTC structured products or hedged via futures, not pure directional bets — confirm counterparty structure. Catalysts: Feb expiries, earnings/FDA for LLY, macro liquidity events.

Trade implications: For GME, prefer defined‑risk long call spreads to participate but limit tail loss; outright short volatility is hazardous given squeeze risk. For LLY, heavy long OTM call flow suggests bullish positioning — adopt directional exposure via call spreads or modest equity buys funded by selling covered calls to capture elevated IV. Across portfolio, implement a calendar/diagonal program: buy longer‑dated calls and sell 30–60d calls to collect premium while capping delta risk; size conservatively given name‑specific gamma.

Contrarian angles: The market may be misreading concentrated option blocks as broad retail mania — a single institutional buyer can create the illusion of consensus. IV is likely overbought for these specific strikes; selling premium with defined risk may be underpriced if you can verify fragmented block origin. Historical parallel: 2021 GME squeezes showed rapid spikes and fast mean reversion — expect high realized vol but limited fundamental follow‑through. Unintended consequence: aggressive shorting of vol could trigger margin cascades if a true squeeze reappears, so cap exposure and enforce hard stops.

Key Decisions for Investors

• GME: Establish a size‑limited (0.5–1.0% portfolio) long, defined‑risk bullish position by buying the Feb 06, 2026 $25/$40 call spread (debit). Risk = premium; take profits at 2x premium or if GME trades down 30% from entry; reduce if intraday move >25% on elevated IV.
• LLY: Take a 1.5% portfolio exposure using a 9–12 month defined‑risk bullish spread: buy Feb 27, 2026 $1220/$1420 call spread sized to risk 1.5% capital. Rationale: participate in call demand while capping capital at known loss; trim if LLY IV falls >30% or stock moves up 20%.
• Volatility program: Implement a 1–2% portfolio calendar strategy across high‑flow names (GME, LLY, AMD) — buy 9–12 month calls and sell 30–60 day calls (1:1) to harvest theta. Hard limits: max aggregate delta exposure 5%, monthly VaR ≤0.5% portfolio, unwind if realized vol exceeds implied by >40%.
• Risk triggers & monitoring: Before increasing exposure verify: (a) single‑buyer evidence (block vs retail), (b) short interest >15% for GME, (c) upcoming earnings/FDA windows for LLY. Immediately reduce options positions if underlying gap >25% intraday, IV moves >40% intraweek, or within 7 days of major expiry/catalyst.